Our laboratory focuses on antibacterial drug discovery to combat antimicrobial resistance (AMR) in bacteria. AMR is amongst the top three threats to global public health defined by WHO in clinical practices. The emergence of antimicrobial resistance in ESKAPE pathogens and Mycobacterium tuberculosis has elevated the burden of diseases and made the known antimicrobials ineffective. This impending health threat problem is more prominent in developing countries like India, where the prevalence of infection is very high and healthcare facilities are limited. We consolidate the clinically pertinent information on the ESKAPE pathogens and M. tuberculosis with relevant microbiological considerations to face the upcoming threat imposed by antimicrobial resistance. This looming health threat has stimulated our interest in developing/identifying therapeutics against ESKAPE or Mtb. The key aim of our group is to portray diverse antimicrobial targets in bacteria for developing antimicrobials. The primary objectives of our lab are;
(1) Development of novel antimicrobial agents to combat the menace caused by Staphylococcus aureus
(2)  Identification & characterization of antimicrobials against Pseudomonas aeruginosa from drug repository
(3) Study of mycobacterial stress response pathways to develop inhibitors of mycobacterial stress signaling pathways
We imply cutting-edge methodologies, including molecular and microbiological tools, synthesis chemistry approaches, protein-compound interaction studies, etc., to set up a drug development/characterization platform. Our team is working on several antibacterial targets and developing/identifying new chemical scaffolds to contribute to the drug discovery pipeline against resistant pathogens.